Allied Health Professional · Neurology ·
FDA News: Three Novel Approvals for Rare and Underserved Conditions (September…
FDA News: Three Novel Approvals for Rare and Underserved Conditions (September 2026)
A quick roundup for colleagues tracking the pipeline:
Zanvastro (Ionis) - approved September 3 as the first treatment for Alexander disease, a rare, progressive neurological disorder.
Fayuvi (Ultragenyx) - a gene therapy cleared September 17 for pediatric patients with Sanfilippo syndrome type A, a condition with no previous approved disease-modifying treatment.
Emcitate (Egetis Therapeutics) - approved September 28 as the first treatment for MCT8 deficiency, a rare inherited thyroid hormone transport disorder.
Why it matters: all three target conditions that previously had no approved therapy. FDA's novel drug approval pace is running ahead of last year, with 44 novel drugs cleared January-September 2026 versus 32 in the same period of 2025.
For clinicians outside these rare-disease subspecialties, the main takeaway is awareness: patients with these diagnoses who were previously offered only supportive care may now have a treatment pathway worth discussing with a specialist centre.